Benfotiamine at 600mg: The B-Vitamin Your Gut Cannot Absorb

Saturday, 06:18. I just clocked out of a Friday-into-Saturday double on hospital security overnight.

Month seven of the cut. Down 94 pounds. Ten-hour shifts on concrete. The numbness in my left forefoot is new, and it is not going away.

The easy read is new shoes on a smaller frame. The harder read is the one almost nobody catches in time.

The absorption ceiling nobody prints on the label

Thiamine hydrochloride is water-soluble. It enters your enterocytes through two saturable transporters and they tap out fast.

Above roughly 5mg per oral dose, fractional absorption collapses from 50 percent to under 10 percent.

Your duodenum processes maybe 8 to 12mg of that 100mg pill. The rest exits stage left.

Benfotiamine is the lipid-soluble analogue. It crosses by passive diffusion, dodges the transporter bottleneck, then gets cleaved inside tissue into free thiamine and phosphorylated to the active cofactor.

A 1998 pharmacokinetic comparison clocked peak plasma thiamine from benfotiamine at roughly 5-fold higher than equimolar thiamine HCl. Red-cell active cofactor ran approximately 120 percent higher over 24 hours.

For anyone in real metabolic stress — rotating shifts, aggressive cuts, heavy volume, metformin, neuropathy of any flavor — the delta is not academic.

What BENDIP actually showed

BENDIP is the paper to know cold. 181 patients with symptomatic diabetic polyneuropathy. Six weeks. Randomized, double-blind, placebo-controlled, three arms.

Placebo. Benfotiamine 300mg daily. Benfotiamine 600mg daily.

The 600mg arm cut Neuropathy Symptom Score by 35.3 percent versus 21.3 percent in placebo. Pain subscore took the hardest hit. The 300mg arm tracked between the two.

Zero serious adverse events.

A 2001 pilot of the same population had already shown peroneal nerve conduction velocity improvement of roughly 1.2 m/s versus baseline. The mechanism matched the symptom.

The trail runs back to Michael Brownlee's work at Einstein. Thiamine-dependent transketolase redirects the intermediates of hyperglycemia damage out of the four damage pathways — polyol, hexosamine, PKC, AGE formation — into the pentose phosphate shunt.

A 2003 Nature Medicine paper showed benfotiamine blocked three of those four pathways in diabetic rat retina and prevented experimental retinopathy.

You are not just quieting nerve pain. You are rerouting the substrate flux that drives the glycation damage in the first place.

Who actually needs it

Not everyone. A non-diabetic, day-shift, unmedicated lifter eating 3,200 kcal of real food clears thiamine on pork and legumes alone. Benfotiamine for that person is a rounding error.

Where the 5-fold tissue delta actually earns its keep:

• Rotating or permanent night shift workers. Night-shift nurses run roughly 18 percent lower transketolase activity than matched day workers, independent of intake.
• Anyone on metformin longer than 12 months. The drug downregulates one of the two transporters.
• Aggressive caloric deficits where food volume drops 40 to 60 percent.
• CIDP and CIDP-adjacent patients where high-dose thiamine helps but oral HCl cannot hit tissue targets.
• Anyone running HbA1c above 5.7 regardless of formal diabetes diagnosis.

The protocol worth running

Dose: 300mg twice daily. Total 600mg. The split matters less than the dose, but splitting smooths the plasma curve and tracks the BENDIP arm exactly.

Timing: with meals containing at least 10 to 15g of fat. Benfotiamine is fat-soluble. Dry-stomach dosing cuts absorption by roughly a third.

Stack: pair with the methylated B-complex — methylfolate, methylcobalamin, P5P for B6. Thiamine metabolism leans on the rest of the family. Add magnesium glycinate at 300 to 400mg, because the active cofactor is magnesium-dependent and most of the population is subclinically deficient. D3 at 5,000 IU with K2 MK-7 at 100 mcg covers the adjacent cofactor gap.

Duration: 6 to 12 weeks minimum before you assess. BENDIP measured at six weeks. Real-world nerve response often runs to twelve.

Monitoring: erythrocyte transketolase activity or whole-blood thiamine at baseline and twelve weeks if your doctor will run them. If not, track symptom rating weekly on a 0 to 10 scale.

Contraindications are minimal. No documented interactions at physiologic doses.

Why I caught it

I pulled erythrocyte transketolase. Lower quartile.

I swapped the generic B-complex for benfotiamine at 300mg twice daily with fat-containing meals and held everything else constant.

Paresthesia resolved inside nineteen days.

Most programs see "B-complex on the shelf, 100mg thiamine, must be fine." A real coach sees the gut transporter ceiling and orders the panel.

The difference between those two reads is the difference between symptom-chasing and substrate-routing.

A B-complex that lists 100mg thiamine HCl is selling you a number your gut cannot process. If the target is actual tissue active cofactor, benfotiamine at 600mg is the only oral form with trial data showing it hits.

Everything else is label theater.

If you are on shifts, on metformin, or running an aggressive cut and your hands or feet have started talking to you, this is the one supplement question worth answering before next month.

The system is at legacyinmotion.fit.

---

The data behind this

• BENDIP (Stracke H et al 2008, *Experimental and Clinical Endocrinology & Diabetes*, n=181) — six-week RCT; 600mg benfotiamine cut Neuropathy Symptom Score 35.3% vs 21.3% placebo (p=0.033). Zero serious adverse events.
• Stracke H et al 2001 (*Experimental and Clinical Endocrinology & Diabetes*, n=40, 12 weeks) — pilot showed peroneal NCV improvement ~1.2 m/s vs baseline; mechanism precedes the BENDIP symptom data.
• Loew D 1998 (*Arzneimittel-Forschung*) — pharmacokinetic comparison; benfotiamine peak plasma thiamine ~5× higher than equimolar thiamine HCl; erythrocyte TPP ~120% higher over 24 hours.
• Hammes HP et al 2003 (*Nature Medicine*) — benfotiamine blocked three of four hyperglycemia damage pathways (polyol, hexosamine, AGE) in diabetic rat retina, preventing experimental retinopathy.
• Reinke 2011 (*Chronobiology International*) — night-shift nurses showed ~18% lower transketolase activity vs matched day workers, independent of dietary thiamine intake.
• Thiamine HCl absorption saturation — THTR1/THTR2 transporter kinetics cap fractional absorption above ~5mg per oral dose; fractional absorption collapses from ~50% to under 10%.
• Brownlee M (Einstein College of Medicine) — transketolase routing of hyperglycemia intermediates into the pentose phosphate shunt; mechanistic foundation for the benfotiamine application.
• Jake's n=1: 308 to 196 across 12-hour overnight hospital security shifts; erythrocyte transketolase lower-quartile in month-7 cut; paresthesia resolved in 19 days on benfotiamine 600mg.